Breast cancer biomarkers, and a new clinical category for HER2 expression

Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients

Frontiers Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents

Cancers, Free Full-Text

HER2 in Breast Cancer: ESMO Biomarker Factsheet

Expanding options for HER2 advanced breast cancer: Taking trial data to the clinic - touchONCOLOGY

An Overview of a Biomarker in Breast Cancer International Journal of Pharmaceutical Investigation

Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer - Laboratory Investigation

Frontiers HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

A Comprehensive Outline Of Trastuzumab Resistance Biomarkers In HER2 Overexpressing Breast Cancer

Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer

Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level

HER2 Positive and Negative Breast Cancers: Aggressiveness, Treatment, and Survival